The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 113, 110453
Abstract
No abstract availableKeywords
Funding Information
- Hokkaido University
This publication has 47 references indexed in Scilit:
- Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulnessTherapeutic Advances in Chronic Disease, 2012
- Prediabetes: a high-risk state for diabetes developmentThe Lancet, 2012
- Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?BMC Psychiatry, 2011
- Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second‐generation antipsychotics: A cross‐sectional study using baseline dataPsychiatry and Clinical Neurosciences, 2011
- Treatment with antipsychotics and the risk of diabetes in clinical practiceThe British Journal of Psychiatry, 2010
- Metabolic side effects of antipsychotic drug treatment – pharmacological mechanismsPharmacology & Therapeutics, 2010
- How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteinsEuropean Psychiatry, 2009
- Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophrenia Research, 2007
- Risk of Diabetes Mellitus Associated With Atypical Antipsychotic Use Among Patients With Bipolar DisorderThe Journal of Clinical Psychiatry, 2006
- Generalized Collinearity DiagnosticsJournal of the American Statistical Association, 1992